Last reviewed · How we verify

Dapsone (Disulone®) — Competitive Intelligence Brief

Dapsone (Disulone®) (Dapsone (Disulone®)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfone antibiotic with immunomodulatory properties. Area: Dermatology, Infectious Disease, Immunology.

phase 3 Sulfone antibiotic with immunomodulatory properties Dihydrofolate reductase; neutrophil function and complement pathway Dermatology, Infectious Disease, Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Dapsone (Disulone®) (Dapsone (Disulone®)) — Assistance Publique - Hôpitaux de Paris. Dapsone is a sulfone antibiotic that inhibits bacterial dihydrofolate reductase and has immunomodulatory properties including suppression of neutrophil function and complement activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dapsone (Disulone®) TARGET Dapsone (Disulone®) Assistance Publique - Hôpitaux de Paris phase 3 Sulfone antibiotic with immunomodulatory properties Dihydrofolate reductase; neutrophil function and complement pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfone antibiotic with immunomodulatory properties class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapsone (Disulone®) — Competitive Intelligence Brief. https://druglandscape.com/ci/dapsone-disulone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: